Rep. April McClain Delaney Sells Off Shares of Labcorp Holdings Inc. (NYSE:LH)

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $100,001 and $250,000 in Labcorp stock on August 25th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of STERIS (NYSE:STE) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.

Labcorp Stock Performance

LH traded up $4.40 during midday trading on Friday, reaching $311.36. The company had a trading volume of 809,927 shares, compared to its average volume of 681,896. The business has a 50-day moving average of $310.39 and a two-hundred day moving average of $281.94. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $341.80. The company has a market cap of $25.25 billion, a P/E ratio of 25.75, a P/E/G ratio of 1.82 and a beta of 0.88.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The firm had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.71 billion. During the same period in the previous year, the firm earned $4.35 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, equities research analysts predict that Labcorp Holdings Inc. will post 18.32 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s payout ratio is 23.82%.

Institutional Trading of Labcorp

Several hedge funds have recently modified their holdings of LH. California State Teachers Retirement System grew its position in Labcorp by 28,952.8% during the 2nd quarter. California State Teachers Retirement System now owns 35,002,800 shares of the medical research company’s stock worth $9,800,784,000 after purchasing an additional 34,882,320 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Labcorp by 103.1% in the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after buying an additional 2,719,475 shares during the last quarter. Boston Partners acquired a new stake in shares of Labcorp during the fourth quarter worth $480,271,000. Norges Bank acquired a new stake in shares of Labcorp during the fourth quarter worth $248,006,000. Finally, Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Labcorp during the second quarter valued at $168,222,000. 95.94% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Labcorp

In related news, Director Kerrii Anderson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the sale, the director owned 6,563 shares in the company, valued at $2,087,165.26. This represents a 31.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan Vaughn sold 234 shares of Labcorp stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the transaction, the executive vice president directly owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. This trade represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,919 shares of company stock worth $2,826,593 over the last 90 days. Insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on LH shares. Morgan Stanley lifted their target price on Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Robert W. Baird set a $352.00 target price on shares of Labcorp in a report on Friday, July 31st. Weiss Ratings upgraded shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Finally, UBS Group increased their price target on Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and an average target price of $336.36.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Labcorp Company Profile

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.